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ABSTRACT
Context: Scopolamine, a muscarinic receptor antagonist, causes memory loss that resembles Alzheimer’s
disease (AD). Echium amoenum L. (Boraginaceae) is a famous medicinal plant of Iran that is traditionally
used as a sedative and mood enhancer.
Objective: This study evaluates the effect of hydroalcoholic extract of E. amoenum flowers on scopolam-
ine-induced memory impairment in rats.
Materials and methods: Fifty male Wistar rats were randomly divided into five groups. Control group
received normal saline, model group received scopolamine (0.7mg/kg, IP, daily for 21 days), and test
groups received E. amoenum extract (50, 75, and 100mg/kg, IP, daily for 21 days) 30min before each sco-
polamine injection. The elevated plus maze (EPM), shuttle box, novel object and rotarod tests were per-
formed after treatment. Brain levels of malondialdehyde (MDA) and total antioxidant capacity (TCA) were
also determined.
Results: Scopolamine-treated rats spent more time exploring the novel object compared to the control,
and E. amoenum extract at all three doses significantly decreased the time spent exploring the novel
object (p< 0.05). E. amoenum extract (75 and 100mg/kg) significantly elongated the secondary latency in
rats receiving scopolamine in the shuttle box test (p< 0.05). In addition, treatment with 75 and 100mg/
kg doses of E. amoenum extract significantly ameliorated scopolamine-induced motor in coordination in
rotarod test (p< 0.05). It also significantly increased the time spent in the open arms and reduced the
time spent in the closed arms of EPM (p< 0.05). Treatment of scopolamine-exposed rats with E. amoenum
extract significantly increased TCA and reduced MDA level of brain (p< 0.05).
Discussion and conclusions: E. amoenum extract shows protective effect against scopolamine-induced
impairment and is suggested to be tested in clinical trials to evaluate the efficacy on AD.
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The prevalence of neurodegenerative diseases, such as
Alzheimer’s disease (AD) and Parkinson’s disease associated with
cognitive and motor impairment, is one of the consequences of
the ageing phenomenon of the world’s population (Kumar and
Singh 2015). AD is a cerebrovascular disorder that gradually
decreases the mental abilities of the patient (Kumar and Singh
2015). Although the main causes of the disease are uncertain,
several factors such as accumulation of b-amyloid and tau pro-
teins, oxidative stress, brain inflammation, as well as inhibition
of cholinergic receptors and decreased cholinergic activity can be
a cause for cognitive impairment in AD (Dolatabadi et al. 2010).
Scopolamine is a muscarinic receptor antagonist, which causes
temporary memory impairment and a pattern similar to that of
AD in animals (Caine et al. 1981). Research has shown that con-
suming different drugs can improve the cognitive and functional
capacity of AD patients, but may also lead to unexpected side
effects (Braak and Braak 1991; Grover et al. 2012). Regarding the
high prevalence of the central nervous system diseases, including
AD, and lack of definitive treatment for these diseases, as well as
the side effects and inadequate efficacy of chemical drugs, there
are studies seeking to find ingredients with satisfactory efficacy
(Ahmad et al. 2014).
Echium amoenum L. (Boraginaceae) is an annual herbaceous
plant that occurs spontaneously and exclusively in the hillsides
of Alborz Mountain Range in Iran and cannot be cultivated. The
plant reaches a height of, at most, 60–100 cm, and its flowers are
blue, pink, red or purple, which, after drying, change into dark
purple or blue (Heidari et al. 2006). E. amoenum is one of the
most important medicinal plants in Iranian traditional medicine,
and its tea is one of the most commonly used herbal drugs. All
parts of the plant, except for root, including stems, leaves and
flowers have pharmaceutical uses (Asadi et al. 2004). E. amoe-
num is widely used as a sedative and mood enhancer. It is also
used to treat cough, sore throat and pneumonia (Behnammanesh
et al. 2015).
Neuroprotective effects of E. amoenum, including anti-ische-
mic (Safaeian et al. 2015), analgesic (Heidari et al. 2006) and
anxiolytic effects (Rabbani et al. 2004), have been shown in ani-
mal models. Recent studies have suggested that the aqueous
extract of E. amoenum is effective in treating patients with mild
to moderate depression (Asadi et al. 2004), as well as obsessive-
compulsive disorder (Asadi et al. 2004), and generalized anxiety
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disorder (Sayyah et al. 2012). Bluish-purple flowers of E. amoe-
num are known as one of the most important sources of phen-
olic compounds such as rosmarinic acid, cyanidin and
delphinidin (Safaeian et al. 2015). Cyanidin-3-glucoside, the most
important anthocyanin in the plant, exhibits protective effects
against brain damage and apoptosis caused by cerebral ischemia
(Min et al. 2011). According to the articles mentioned above, it
seems that E. amoenum is effective against cognitive impairments
caused by neurodegenerative diseases. Therefore, this study eval-
uates the effect of E. amoenum extract on scopolamine-induced
memory impairment in rats.
Materials and methods
Preparation of E. amoenum extract
The flowers of E. amoenum, were purchased from a local market
of Shahrekord, Iran in July 2017 and identified by Dr Rafieian,
herbalist, and then a reference sample was kept in the
Herbarium of Islamic Azad University of Izeh (voucher No.
549). The extraction was conducted by a maceration method.
The dried plant sample (1 kg) was pulverized by an electric mill
and then mixed with 70% ethanol at 1:5 sample/solvent ratio
(w/v). After 72 h, the solution was filtered through Whatman fil-
ter paper No. 1 and the filtrate evaporated under vacuum at
40 C to dryness. Finally, the resulting solution was completely
dried at 37 ± 1 C. The percentage of crude hydroalcoholic extract
yield from the dried flowers of E. amoenum was 3% (w/w).
Grouping and treatment of animals
Male Wistar rats weighing 200–250 g were kept in controlled
conditions (21 ± 2 C, 12 h light/dark cycle) with free access to
water and food. Rats were then randomly assigned into five
groups of 10 each. The control group received normal saline
(1mL/kg) for 21 days. The scopolamine group intraperitoneally
received scopolamine at a dose of 0.7mg/kg for 21 days. Extract
treated groups intraperitoneally received scopolamine and then
E. amoenum extract at 50, 75, and 100mg/kg for 21 days.
Behavioural tests were conducted for several days from day 21.
The selection of the doses of scopolamine and E. amoenum
extract based on previously published studies (Asgharzade et al.
2015; Safaeian et al. 2015). After behavioural tests, rat underwent
general anesthesia using Chloral hydrate (800mg/kg) and sample
of brain tissue was obtained and stored at -70 C for biochem-
ical assays.
Shuttle box test
Passive avoidance memory was measured by shuttle box. This
apparatus has a bright chamber connected to a dark chamber by
a guillotine door. Electric shocks are exerted to a conductive
metal grid on the floor of the apparatus by a separate stimulus.
This test was performed on each rat for four consecutive days.
On the first two days, rats were individually allowed to freely
explore the apparatus for 5min. On the third day, an acquisition
test was conducted. Rats were left in the bright chamber and,
after 2min acclimatization, the guillotine door was opened and
after the animal entry into the dark chamber, it was closed and
an electrical shock (1mA/s) was exerted to it and the latency to
enter the dark chamber was recorded as initial latency. Twenty-
four hours later, each rat was placed in the bright chamber and
latency to enter the dark chamber was measured as secondary
latency (up to 60 s) (Rabiei et al. 2015).
Novel object test
In novel object test, animals were tested using a
50 25 50 25 cm open black box for two consecutive days.
On the first day, animals were placed in the apparatus without
objects and permitted to explore for 5min. On the second day,
two equal objects were presented for exploration (T1). Object
exploration was defined as sniffing or touching the object at
<2 cm from the nose or exploring both the objects for 10 s.
After identification, T1 trial was terminated and animal was
taken back to its home cage. T2 trial was performed 24 h later.
In this step, animal was permitted to freely explore a novel and
familiar object for 4min. In order to reduce the effect of place
and object preference, two objects were randomly placed in the
apparatus. The time spent to explore the new and familiar
objects was rerecorded on video trap (Karasawa et al. 2008).
Rotarod performance test
The ability to maintain balance and motor resistance was investi-
gated using rotarod. This apparatus has a rod that rotates at a
speed of 0–40 rpm. The apparatus also has a belt and the speed
of the rod can be adjusted by changing the belt position. First,
the animal was placed on the rotating rod of the apparatus and
trained to walk on it according to the main protocol (10 rpm
and 7 rpm2 acceleration). Thirty minutes later, the rat was again
placed on the rod and the time to maintain balance and resist
rod movement was recorded. The maximum time for each ani-
mal in this test was considered to be 300 s (Asgharzade
et al. 2015).
Elevated plus maze (EPM) test
An apparatus called elevated plus maze was used to measure
anxiety. This apparatus has two opposite open arms, two oppos-
ite closed arms, and a central sheath elevated 50 cm above the
floor. This test was performed in a relatively dark, silent cham-
ber, and each animal was placed gently in the center of the
device facing the open arm and allowed to explore for 5min.
The number of entries and time spent in each arm were
recorded (Lee et al. 2014).
Measuring total antioxidant capacity (TCA)
Total antioxidant capacity of brain tissue homogenate was deter-
mined by the Ferric ion reducing antioxidant power (FRAP).
The FRAP solution was prepared by adding 2.5mL of 0.25mM
acetate buffer with pH 3, 2.5mL of 10mM 2,4,6-Tris(2-pyridyl)-
s-triazine (TPTZ), prepared in 40mM hydrochloric acid, and
2.5mL of 20mM 6H2O FeCl. The tissue homogenate sample
(25 lL) was mixed with 1.5mL of FRAP working solution, and
the optical absorbance of the resulting mixture was read by the
spectrophotometer at 593 nm, after it was left at 37 C for 10min
(El-Sherbiny et al. 2003).
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Measuring malondialdehyde (MDA) level
Brain tissue homogenate (25 lL) was mixed with 1.5mL of acetic
acid 20%, 1.5mL of 0.8mM thiobarbituric acid (TBA), and
200lL of SDS 1.8% solution. The sample was then placed in
boiling water for 60min. The sample was cooled and 1mL of
distilled water and 5mL of n-butanol-pyridine solution added to
it and the resulting mixture was shaken. The mixture was then
centrifuged for 10min at 4000 rpm and the optical absorbance of
the supernatant was recorded at 523 nm (Ben-Nasr et al. 2015).
Data analysis
Data were entered into the SPSS version 21 (SPSS lnc. Chicago,
IL, USA). One-way ANOVA followed by Tukey’s test was used
to analyse the data. The data were expressed as mean ± standard
deviation (SD) and p< 0.05 was considered significance level.
Results
The results from the novel object identification test are illus-
trated in Figure 1. According to the results, the time taken to
identify the new object was significantly higher in the scopolam-
ine group than in the controls (p< 0.001). Treatment with E.
amoenum extract at 50, 75 and 100mg/kg in rats given scopol-
amine caused a significant decrease in the time taken to identify
the new object when compared to the scopolamine receiving rats
(p< 0.001 and p< 0.01, respectively).
The results of the initial and secondary latencies in the pas-
sive avoidance task are illustrated in Figure 2. According to the
results, there was no significant difference in the initial latency
to enter the dark chamber between the groups. Secondary latency
time was significantly lower in the scopolamine receiving group
than in the control group (p< 0.001). Treatment of rats receiving
scopolamine with E. amoenum extract at 75 and 100mg/kg
caused a significant increase in secondary latency
time (p< 0.001).
The results on the duration of the balance in the rotarod test
in different groups are illustrated in Figure 3. The duration of
balance in the scopolamine group was significantly lower than
that in the control group (p< 0.01) and the treatment with the
extract of E. amoenum at 75 and 100mg/kg caused a significant
improvement of the balance duration (p< 0.01 and p< 0.05,
respectively).
As illustrated in Figure 4, scopolamine exposure significantly
increased time spent in the closed arms and reduced time spent
in the open arms of elevated plus maze (p< 0.001). Treatment of
rats given scopolamine with E. amoenum extract at 75 and
100mg/kg significantly reduced the time spent in the closed
arms and increased the time spent in the open arms (p< 0.001).
As the results in Table 1 show, in rats treated with scopolam-
ine a significant increase in the brain MDA level was noted
(p< 0.001). Administration of E. amoenum extract at 75 and
100mg/kg significantly reduced the brain MDA as compared
with the scopolamine-treated group (p< 0.001).
As the results in Table 2 show, the treatment of rats with sco-
polamine significantly reduced the antioxidant capacity of brain
(p< 0.001). The antioxidant capacity of brain showed significant
improvement in animal treated with E. amoenum extract at 50,
75 and 100mg/kg (p< 0.001).
Discussion
In the present study, the protective effects of hydroalcoholic
extract of E. amoenum on scopolamine-induced learning and
memory impairments were investigated. Treatment of rats by
sequential injections of scopolamine for 21 days resulted in
impaired memory function accompanied by shorter step through
latency in the shuttle box and lower new object exploration time
in the novel object test. It was previously shown that scopolam-
ine exposure impairs memory and learning capacity in shuttle
box and also novel object test (Bartolini et al. 1996; Seifhosseini
et al. 2011). Scopolamine, a muscarinic receptor antagonist, read-
ily passes the blood brain barrier to induce anti-muscarinic activ-
ity leading to cholinergic deficit and memory loss. As an age-
related decline in memory function is thought to be prominently
due to impairment of cholinergic neurotransmission, scopolam-
ine exposure has often been applied to induce experimental
dementia to assess new drugs for learning and memory impair-
ments (Stone et al. 1988, 1991). Our data demonstrated that
extract of E. amoenum shows potent memory enhancing effects
in both shuttle box and novel object tests. To our knowledge,
there was no previous study on memory-enhancing activity of E.
amoenum, but rosmarinic acid which found in this plant shows
considerable cholinergic activity and improves scopolamine-
induced memory loss (Hasanein and Mahtaj 2015).
In our study, scopolamine exposure also induced anxiety like
behaviours in the elevated plus maze and reduced balance in the
rotarod test which is in judgement with previous studies
(Rahmati et al. 2017). In our study, E. amoenum extract at 75
and 100mg/kg significantly ameliorated anxiety-like behaviours
and improved ability to maintain balance on the rotarod.
Consistent with the present results, the anti-anxiety effects of E.
amoenum were shown in the mouse model (Shafaghi et al. 2010)
and also double-blind clinical trial (Shafaghi et al. 2010; Sayyah
et al. 2012).
In the present study, scopolamine injection caused a signifi-
cant reduction in the antioxidant capacity of brain and a signifi-
cant increase in its MDA, as the index of lipid peroxidation. It is
well known that scopolamine causes memory impairment by
attenuating cholinergic neurotransmission, as well as increases of
markers of oxidative stress in the brain (Budzynska et al. 2015).
Figure 1. Comparison of the results of novel object recognition test between
groups.  Shows significant differences with control group (p< 0.001).
# Shows significant differences with scopolamine treated group (###p< 0.001,
##p< 0.01). SCO¼ Scopolamine, SCOþ EA 50, 75 and 100¼ scopolamine plus
E. amoenum extract at doses of 50, 75 and 100mg/kg.
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Figure 2. Comparison of the initial (a) and secondary (b) latency time in shuttle box test between groups. Shows significant differences with control group
(p< 0.001). # Shows significant differences with scopolamine treated group (###p< 0.001). SCO¼ Scopolamine, SCOþ EA 50, 75 and 100¼ scopolamine plus
E. amoenum extract at doses of 50, 75 and 100mg/kg.
Figure 3. Comparison of the balance maintenance time in rotarod test between
groups.  Shows significant differences with control group (p< 0.01). # Shows
significant differences with scopolamine treated group (##p< 0.001, #p< 0.05).
SCO¼ Scopolamine, SCOþ EA 50, 75 and 100¼ scopolamine plus E. amoenum
extract at doses of 50, 75 and 100mg/kg.
Figure 4. Comparison of the time spent in the closed (a) and open (b) arms of the elevated plus maze (EPM) between groups.  Shows significant differences with
control group (p< 0.001, p< 0.01). # Shows significant differences with scopolamine treated group (###p< 0.001). SCO¼ Scopolamine, SCOþ EA 50, 75 and
100¼ scopolamine plus E. amoenum extract at doses of 50, 75 and 100mg/kg.
Table 1. Comparison of brain malondialdehyde (MDA) levels between groups.
Groups MDA(mmol/g)
Control 132.85 ± 32.05
SCO 342.25 ± 81.64
SCOþ EA 50 287.00 ± 52.24
SCOþ EA 75 162.42 ± 15.30###
SCOþ EA 100 144.00 ± 44.08###
 Shows significant differences with control group (p< 0.001). # Shows
significant differences with scopolamine treated group (###p< 0.001).
SCO¼ Scopolamine, SCOþ EA 50, 75 and 100¼ scopolamine plus E. amoenum
extract at doses of 50, 75 and 100mg/kg.
Table 2. Comparison of brain total antioxidant capacity (TCA) between groups.
Groups TCA (mmol/g)
Control 859.64 ± 70.05
SCO 215.99 ± 44.08
SCOþ EA 50 550.97 ± 64.81###
SCOþ EA 75 556.45 ± 24.52###
SCOþ EA 100 711.55 ± 30.15###
 Shows significant differences with control group (p< 0.001). # Shows
significant differences with scopolamine treated group (###p< 0.001).
SCO¼ Scopolamine, SCOþ EA 50, 75 and 100¼ scopolamine plus E. amoenum
extract at doses of 50, 75 and 100mg/kg.
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Experimental studies have found that injection of scopolamine in
rats induces the peroxidation of lipids and weakens intrinsic
antioxidant defenses in whole brain, as well as in regions associ-
ated with memory and learning process (Kwon et al. 2010).
Brain is particularly vulnerable to oxidative stress due to the
high content of highly oxidizable polyunsaturated fatty acids and
the relatively low antioxidant defenses in comparison with other
tissues. During oxidative stress, overproduced ROS can react
with vital cellular components such as proteins, nucleic acids,
lipids and carbohydrates leading to neuronal cell damage and
apoptosis, and ultimately impaired memory and learning func-
tion (Markesbery 1997). In our study, E. amoenum extract treat-
ment significantly attenuated thescopolamine-induced lipid
peroxidation and reduced antioxidant capacity. Antioxidant func-
tion of E. amoenum has been previously reported. In a study of
37 healthy volunteers, daily consumption of E. amoenum at
7mg/kg enhanced serum antioxidant capacity and significantly
decreased lipid peroxidation (Ranjbar et al. 2006). The antioxi-
dant effects of E. amoenum have been attributed to the presence
of phenolic compounds flavonoids, b-carotene, vitamin C, antho-
cyanins, and tannins (Pilerood and Prakash 2014). It has been
reported that one of the main phenolic compounds of the plant,
rosmarinic acid, exhibits protective effects against oxidative damage
of dopaminergic neurons caused by hydrogen peroxide (Lee et al.
2008). Cyanidin and delphinidin, found in abundance in E. amoe-
num extract, decrease the production of hydrogen peroxide and
increase the activity of glutathione reductase and glutathione con-
tent in cell culture media (Cvorovic et al. 2010). Accordingly, it can
be argued that E. amoenum extract can prevent oxidative damage
to the neurons and subsequent memory function degradation.
Inflammatory processes play an important role in the patho-
genesis of degenerative changes and cognitive impairment associ-
ated with AD (Heneka et al. 2015). Brain inflammatory markers
[cyclooxygenase 1 (COX-1), cyclooxygenase 2 (COX-2), IL-1b,
and IL-10)] have been reported to increase in scopolamine-
induced memory loss (Ahmad et al. 2014). Scopolamine activates
the NF-jB pathway in neurons. This transcription factor can
increase the expression of genes such as TNF-a, iNOS and COX-
2 (Jang et al. 2013). In addition, studies have shown that anti-
inflammatory drugs have a positive effect on cognitive function
in mice treated with lipopolysaccharide and scopolamine (Jain
et al. 2002) Cyanidin-3 glucoside, one of the most abundant
anthocyanin in E. amoenum extract reduces the production of
inflammatory agents such as prostaglandin E2, and COX-2 in
cancer cells by inhibiting the activation of the transcription fac-
tor C-jun and NF-jB (Munoz-Espada and Watkins 2006).
Delphinidin, another anthocyanin of the plant, directly inhibits
the activity of kinase Fyn and thus reduces TNF-a-induced
COX-2 expression (Hwang et al. 2009). Therefore, due to the
anti-inflammatory activity of E. amoenum and its active ingre-
dients, inflammatory mechanisms can be considered to be the
major mechanisms involved in the plant activity, although it is
necessary to further investigate this argument in future studies.
Echium amoenum is used in Iranian traditional medicine to
reduce anxiety and tension and produce calming effects. However,
few studies have been conducted on neuroprotective effects of the
plant in animal models as well as clinical trials. There is very limited
information on plant active ingredients and the mechanism of neu-
roprotective effects, which requires further research in this regard.
Conclusions
The present study indicated the efficacy of E. amoenum extract
in improving scopolamine-induced memory impairment, anxiety
and imbalance via antioxidant activity and reducing brain lipid
peroxidation. Therefore, an investigation on cognitive functions,
motor imbalance, and psychiatric disorders in AD patients is
recommended.
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